$6.98
4.33%
Nasdaq, Oct 03, 10:00 pm CET
ISIN
US0050831009
Symbol
ACTU

Actuate Therapeutics Stock price

$6.98
-1.63 18.93% 1M
-0.24 3.32% 6M
-0.98 12.31% YTD
-0.03 0.40% 1Y
-1.02 12.75% 3Y
-1.02 12.75% 5Y
-1.02 12.75% 10Y
-1.02 12.75% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
+0.29 4.33%
ISIN
US0050831009
Symbol
ACTU
Industry

Key metrics

Basic
Market capitalization
$162.2m
Enterprise Value
$156.2m
Net debt
positive
Cash
$6.5m
Shares outstanding
20.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
1.1%
Return on Equity
-26,235.9%
ROCE
1,073.7%
ROIC
-
Debt/Equity
-0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-23.9m | $-24.7m
Net Income
$-24.7m | $-24.1m
Free Cash Flow
$-22.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | 1.9%
Net Income
- | 11.6%
Free Cash Flow
6.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.3
FCF per Share
$-1.1
Short interest
5.8%
Employees
-
Rev per Employee
-
Show more

Is Actuate Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Actuate Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Actuate Therapeutics forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Actuate Therapeutics forecast:

Buy
90%
Hold
10%

Financial data from Actuate Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
-
-
- Research and Development Expense 13 13
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -24 -24
-
-
Net Profit -25 -25
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Actuate Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Actuate Therapeutics Stock News

Neutral
GlobeNewsWire
13 days ago
CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced a corporate update on the regulatory pa...
Neutral
GlobeNewsWire
25 days ago
CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it has priced an underwritten publ...
Neutral
GlobeNewsWire
26 days ago
CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it intends to offer and sell share...
More Actuate Therapeutics News

Company Profile

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Head office United States
CEO Daniel Schmitt
Website actuatetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today